NEWBRY — Newbury Pharmaceuticals AB Cashflow Statement
0.000.00%
Last trade - 00:00- SEK62.40m
- SEK50.73m
- SEK36.83m
- 35
- 37
- 17
- 16
Annual cashflow statement for Newbury Pharmaceuticals AB, fiscal year end - August 31st, SEK millions except per share, conversion factor applied.
2021 August 31st | 2022 August 31st | 2023 August 31st | 2024 August 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS |
| Standards: | SAS | SAS | SAS | SAS |
| Status: | Final | Final | Final | Final |
| Net Income/Starting Line | -5.56 | -14.7 | -19.4 | -15.4 |
| Non-Cash Items | 0.608 | 1.03 | 1.57 | 1.52 |
| Other Non-Cash Items | ||||
| Changes in Working Capital | 0.883 | -1.36 | -5.37 | -9.82 |
| Change in Accounts Receivable | ||||
| Change in Inventories | ||||
| Change in Accounts Payable | ||||
| Change in Other Liabilities | ||||
| Net Change in Other Assets & Liabilities | ||||
| Cash from Operating Activities | -4.07 | -15 | -23.2 | -23.7 |
| Capital Expenditures | -23.1 | -24.4 | -0.862 | -2.91 |
| Purchase / Acquisition of Intangibles | ||||
| Other Investing Cash Flow Items | -3.65 | 0 | 0 | -0.045 |
| Change in Net Investments | ||||
| Cash from Investing Activities | -26.7 | -24.4 | -0.862 | -2.95 |
| Net Issuance / Retirement of Stock | ||||
| Net Issuance / Retirement of Debt | ||||
| Cash from Financing Activities | 43.9 | 59.6 | -0.717 | 33.4 |
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | 13.1 | 20.2 | -24.8 | 6.78 |